Protagenic Therapeutics, Inc.\new Quarterly Debt-to-equity in % from Q1 2015 to Q2 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Protagenic Therapeutics, Inc.\new quarterly Debt-to-equity history and growth rate from Q1 2015 to Q2 2024.
  • Protagenic Therapeutics, Inc.\new Debt-to-equity for the quarter ending June 30, 2024 was 28.4 %, a 56.4% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2024 28.4 +10.3 +56.4% Jun 30, 2024
Q1 2024 25.3 +11.5 +83.2% Mar 31, 2024
Q4 2023 23.9 +11.7 +95.2% Dec 31, 2023
Q3 2023 22.5 +11.4 +102% Sep 30, 2023
Q2 2023 18.2 -7.44 -29% Jun 30, 2023
Q1 2023 13.8 -11.1 -44.5% Mar 31, 2023
Q4 2022 12.2 -57.5 -82.4% Dec 31, 2022
Q3 2022 11.2 +261 Sep 30, 2022
Q2 2022 25.6 -87.2 -77.3% Jun 30, 2022
Q1 2022 24.9 +195 Mar 31, 2022
Q4 2021 69.7 +285 Dec 31, 2021
Q3 2021 -250 -15.2 -6.48% Sep 30, 2021
Q2 2021 113 Jun 30, 2021
Q1 2021 -170 Mar 31, 2021
Q4 2020 -215 Dec 31, 2020
Q3 2020 -235 Sep 30, 2020
Q4 2015 -136 Dec 31, 2015
Q3 2015 -163 Sep 30, 2015
Q2 2015 -205 Jun 30, 2015
Q1 2015 -294 Mar 31, 2015
* An asterisk sign (*) next to the value indicates that the value is likely invalid.